Evaluation of combined (177)Lu-DOTA-8-AOC-BBN (7-14)NH(2) GRP receptor-targeted radiotherapy and chemotherapy in PC-3 human prostate tumor cell xenografted SCID mice (Q37106150)

From Wikidata

Jump to navigation Jump to search

scientific article published on April 2006

Language	Label	Description	Also known as
English	Evaluation of combined (177)Lu-DOTA-8-AOC-BBN (7-14)NH(2) GRP receptor-targeted radiotherapy and chemotherapy in PC-3 human prostate tumor cell xenografted SCID mice	scientific article published on April 2006

Statements

scholarly article

1 reference

Europe PubMed Central

18 August 2017

Evaluation of combined (177)Lu-DOTA-8-AOC-BBN (7-14)NH(2) GRP receptor-targeted radiotherapy and chemotherapy in PC-3 human prostate tumor cell xenografted SCID mice (English)

1 reference

Europe PubMed Central

18 August 2017

Adaptive radiation therapy

0 references

prostate neoplasm

1 reference

based on heuristic

inferred from title

author name string

Christopher V Johnson

1

1 reference

Europe PubMed Central

18 August 2017

Tiffani Shelton

2

1 reference

Europe PubMed Central

18 August 2017

Charles J Smith

3

1 reference

Europe PubMed Central

18 August 2017

Lixin Ma

4

1 reference

Europe PubMed Central

18 August 2017

Michael C Perry

5

1 reference

Europe PubMed Central

18 August 2017

Wynn A Volkert

6

1 reference

Europe PubMed Central

18 August 2017

Timothy J Hoffman

7

1 reference

Europe PubMed Central

18 August 2017

publication date

1 April 2006

1 reference

Europe PubMed Central

18 August 2017

Cancer Biotherapy and Radiopharmaceuticals

1 reference

Europe PubMed Central

18 August 2017

21

1 reference

Europe PubMed Central

18 August 2017

2

1 reference

Europe PubMed Central

18 August 2017

155-166

1 reference

Europe PubMed Central

18 August 2017

Peptide receptor radionuclide therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646369

14 September 2017

Gastrin releasing peptide (GRP) receptor targeted radiopharmaceuticals: a concise update

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646369

14 September 2017

Molecular characterization of human prostate carcinoma cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646369

14 September 2017

Chemotherapy for androgen-independent prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646369

14 September 2017

Docetaxel in the integrated management of prostate cancer. Current applications and future promise.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646369

14 September 2017

Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646369

14 September 2017

Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646369

14 September 2017

Radiometallated receptor-avid peptide conjugates for specific in vivo targeting of cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646369

14 September 2017

Docetaxel in prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646369

14 September 2017

Receptor targeting for tumor localisation and therapy with radiopeptides

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646369

14 September 2017

Docetaxel (Taxotere) in hormone-refractory prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646369

14 September 2017

Taxanes: an overview of the pharmacokinetics and pharmacodynamics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646369

14 September 2017

Hormone-refractory prostate cancer: an evolving standard of care.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646369

14 September 2017

Daily oral estramustine and intermittent intravenous docetaxel (Taxotere) as chemotherapeutic treatment for metastatic, hormone-refractory prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646369

14 September 2017

Stabilization of microtubule dynamics by estramustine by binding to a novel site in tubulin: a possible mechanistic basis for its antitumor action

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646369

14 September 2017

MOLMOL: a program for display and analysis of macromolecular structures

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646369

14 September 2017

Establishment and characterization of a human prostatic carcinoma cell line (PC-3)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646369

14 September 2017

Preliminary evaluation of a short course of estramustine phosphate and docetaxel (Taxotere) in the treatment of hormone-refractory prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646369

29 September 2017

Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646369

29 September 2017

Preclinical pharmacology and toxicology of estramustine phosphate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646369

29 September 2017

Mode of action of emcyt

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646369

29 September 2017

Clinical pharmacokinetics of estramustine phosphate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646369

29 September 2017

Estramustine-based chemotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646369

29 September 2017

Characterization of high-affinity receptors for bombesin/gastrin releasing peptide on the human prostate cancer cell lines PC-3 and DU-145: internalization of receptor bound 125I-(Tyr4) bombesin by tumor cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646369

29 September 2017

Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646369

27 June 2018

Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646369

27 June 2018

A weekly schedule of docetaxel for metastatic hormone-refractory prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646369

3 September 2018

Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646369

3 September 2018

Radiochemical investigations of gastrin-releasing peptide receptor-specific [(99m)Tc(X)(CO)3-Dpr-Ser-Ser-Ser-Gln-Trp-Ala-Val-Gly-His-Leu-Met-(NH2)] in PC-3, tumor-bearing, rodent models: syntheses, radiolabeling, and in vitro/in vivo studies where D

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646369

3 September 2018

Radiochemical investigations of [188Re(H2O)(CO)3-diaminopropionic acid-SSS-bombesin(7-14)NH2]: syntheses, radiolabeling and in vitro/in vivo GRP receptor targeting studies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646369

3 September 2018

Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646369

3 September 2018

Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium-DOTA-peptide-ChL6.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646369

3 September 2018

Weekly docetaxel and estramustine in patients with hormone-refractory prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646369

3 September 2018

Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646369

3 September 2018

Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646369

3 September 2018

Role of wild-type p53 in the enhancement of camptothecin cytotoxicity against human prostate tumor cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646369

3 September 2018

Cytotoxic properties of estramustine unrelated to alkylating and steroid constituents.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646369

3 September 2018

Treatment of androgen-independent prostate cancer using antimicrotubule agents docetaxel and estramustine in combination: an experimental study

1 reference

https://pubmed.ncbi.nlm.nih.gov/16706636

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Radiochemical investigations of 177Lu-DOTA-8-Aoc-BBN[7-14]NH2: an in vitro/in vivo assessment of the targeting ability of this new radiopharmaceutical for PC-3 human prostate cancer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/16706636

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Novel series of 111In-labeled bombesin analogs as potential radiopharmaceuticals for specific targeting of gastrin-releasing peptide receptors expressed on human prostate cancer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/16706636

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Estramustine potentiates the radiation effect in human prostate tumor transplant in nude mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/16706636

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fas-mediated apoptosis in human prostatic carcinoma cell lines

1 reference

https://pubmed.ncbi.nlm.nih.gov/16706636

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Radioiodinated estramustine phosphate and estramustine binding protein antibody accumulate in the prostate of a mouse

1 reference

https://pubmed.ncbi.nlm.nih.gov/16706636

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Antimitotic agents]

1 reference

https://pubmed.ncbi.nlm.nih.gov/16706636

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Body condition scoring: a rapid and accurate method for assessing health status in mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/16706636

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1089/CBR.2006.21.155

1 reference

Europe PubMed Central

18 August 2017

1 reference

Europe PubMed Central

18 August 2017

1 reference

Europe PubMed Central

18 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37106150&oldid=2095065277"